SCHEMBL2729079

SCHEMBL2729079

CC1OC(=O)c2ccc(Br)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.42
S100A4 P26447 1/20 0.41
PTPRC P08575 1/20 0.40
MAPK1 P28482 2/20 0.39
CYP1A2 P05177 1/20 0.39
AKT1 P31749 1/20 0.39
LMNA P02545 1/20 0.37
AR P10275 1/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
BCL2 P10415 1/20 0.35
MCL1 Q07820 1/20 0.35
CA4 P22748 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
TDP2 O95551 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30553000 1.00 PBRM1 (0.42) PBRM1S100A4PTPRCMAPK1CYP1A2
SCHEMBL6669536 0.85 PBRM1 (0.46) PBRM1S100A4PTPRCMAPK1CYP1A2
SCHEMBL30512948 0.80 PBRM1 (0.39) PBRM1S100A4PTPRCMAPK1CYP1A2
SCHEMBL30512991 0.80 PBRM1 (0.39) PBRM1S100A4PTPRCMAPK1CYP1A2
SCHEMBL25409903 0.80 PBRM1 (0.39) PBRM1S100A4PTPRCMAPK1CYP1A2
SCHEMBL25411311 0.80 PBRM1 (0.39) PBRM1S100A4PTPRCMAPK1CYP1A2
SCHEMBL25409901 0.80 PBRM1 (0.39) PBRM1S100A4PTPRCMAPK1CYP1A2
SCHEMBL86917 0.79 S100A4 (0.42) PBRM1S100A4PTPRCMAPK1CYP1A2
SCHEMBL25261284 0.78 TYMS (0.42) S100A4AKT1ARCA1CA2
SCHEMBL20354665 0.78 MAOB (0.40) AKT1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116891448-A Preparation method of roflumilast intermediate III 上海医药集团青岛国风药业股份有限公司 2023-10-17 CN claimed
CN-113754569-B Intermediate compound and preparation method and application thereof 四川国为制药有限公司 2024-07-02 CN disclosed
CN-116891448-A Preparation method of roflumilast intermediate III 上海医药集团青岛国风药业股份有限公司 2023-10-17 CN disclosed
WO-2023134656-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF 上海壹典医药科技开发有限公司 2023-07-20 WO disclosed
WO-2023134656-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF 上海壹典医药科技开发有限公司 2023-07-20 WO disclosed
CN-113754569-A Intermediate compound and preparation method and application thereof 四川国为制药有限公司 2021-12-07 CN disclosed
CN-112375057-A Preparation method of intermediate IV of roxasistat 天津敬康生物科技有限公司 2021-02-19 CN disclosed
US-20170275302-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. 2017-09-28 US disclosed
US-9056859-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2015-06-16 US disclosed
EP-2632464-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2015-04-29 EP disclosed
EP-2632464-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL Merck Sharp & Dohme Corp. (US) 2013-09-04 EP disclosed
US-20130217680-A1 Inhibitors of the Renal Outer Medullary Potassium Channel MERCK SHARP & DOHME LLC 2013-08-22 US disclosed
WO-2012058134-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275302-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, KCNJ2 PBRM1 3067/4885S100A4 4789/4885PTPRC 3620/4885
US-20130217680-A1 Inhibitors of the Renal Outer Medullary Potassium Channel KCNJ11, KCNJ1, KCNJ2 PBRM1 3489/4885S100A4 4762/4885PTPRC 3657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.